William Blair & Company
KRYS icon

William Blair & Company’s Krystal Biotech KRYS Stock Holding History

William Blair & Company’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$632K Sell
2,448
-729
-23% -$194K ﹤0.01% 1064
2025
Q4 		$783K Sell
3,177
-1,575
-33% -$331K ﹤0.01% 1001
2025
Q3 		$839K Sell
4,752
-100
-2% -$15K ﹤0.01% 965
2025
Q2 		$667K Sell
4,852
-4,581
-49% -$673K ﹤0.01% 1003
2025
Q1 		$1.7M Buy
9,433
+1,990
+27% +$335K 0.01% 754
2024
Q4 		$1.17M Buy
7,443
+1,875
+34% +$333K ﹤0.01% 853
2024
Q3 		$1.01M Buy
5,568
+2
+0% +$386 ﹤0.01% 902
2024
Q2 		$1.02M Sell
5,566
-36
-0.6% -$6.04K ﹤0.01% 868
2024
Q1 		$997K Sell
5,602
-550
-9% -$76.4K ﹤0.01% 869
2023
Q4 		$763K Buy
6,152
+20
+0.3% +$2.22K ﹤0.01% 945
2023
Q3 		$711K Sell
6,132
-885
-13% -$108K ﹤0.01% 945
2023
Q2 		$824K Sell
7,017
-40
-0.6% -$4.08K ﹤0.01% 910
2023
Q1 		$565K Buy
7,057
+100
+1% +$7.86K ﹤0.01% 1000
2022
Q4 		$551K Buy
6,957
+580
+9% +$43K ﹤0.01% 1012
2022
Q3 		$444K Buy
6,377
+1,285
+25% +$92.8K ﹤0.01% 1085
2022
Q2 		$334K Buy
+5,092
New +$317K ﹤0.01% 1222
2022
Q1 		– Sell
-8,896
Closed -$622K – 1958
2021
Q4 		$622K Sell
8,896
-84,242
-90% -$4.9M ﹤0.01% 1131
2021
Q3 		$4.86M Buy
93,138
+34,383
+59% +$2.04M 0.02% 463
2021
Q2 		$4M Buy
58,755
+4,589
+8% +$320K 0.01% 511
2021
Q1 		$4.17M Buy
54,166
+18,908
+54% +$1.37M 0.02% 495
2020
Q4 		$2.12M Sell
35,258
-761
-2% -$38K 0.01% 635
2020
Q3 		$1.55M Sell
36,019
-13,880
-28% -$603K 0.01% 649
2020
Q2 		$2.07M Sell
49,899
-10,982
-18% -$528K 0.01% 547
2020
Q1 		$2.63M Sell
60,881
-2,873
-5% -$150K 0.02% 458
2019
Q4 		$3.53M Buy
63,754
+5,263
+9% +$258K 0.02% 476
2019
Q3 		$2.03M Buy
58,491
+39,225
+204% +$1.75M 0.01% 568
2019
Q2 		$776K Sell
19,266
-46,940
-71% -$1.53M ﹤0.01% 834
2019
Q1 		$2.18M Buy
66,206
+44,426
+204% +$1.05M 0.01% 535
2018
Q4 		$453K Buy
+21,780
New +$456K ﹤0.01% 937

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

William Blair & Company's KRYS Position: Q1 2026 in Review

William Blair & Company reduced its Krystal Biotech (KRYS) stake by 23% in Q1 2026, selling an estimated $194K and leaving 2,448 shares worth $632K. The position accounts for ﹤0.01% of the portfolio, ranked #1064.

William Blair & Company first reported a position in KRYS in Q4 2018 and has held it in 29 quarters since. The position peaked at $4.86M in Q3 2021. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • William Blair & Company held 2,448 shares of Krystal Biotech worth $632K as of Q1 2026.
  • William Blair & Company sold 729 Krystal Biotech shares in Q1 2026, an estimated $194K.
  • Krystal Biotech made up ﹤0.01% of William Blair & Company's portfolio in Q1 2026, its #1064 holding.
  • William Blair & Company first reported a position in Krystal Biotech in Q4 2018 and has held it in 29 quarters since.
  • William Blair & Company's Krystal Biotech position peaked at $4.86M in Q3 2021.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.